Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer

Table 9

The relationship between the development of rash and clinical outcome when using anti-EGFR mAbs in mCRC.

Trial (first author)	KRAS	Protocol	Grade of rash	Results		HR (95% CI)	𝑃 value
				PFS	OS
— (O’Callaghan et al.) [44]	WT	BSC versus	0/1	1.9 mos.	5 mos.	PFS: 0.57 (0.38–0.86); OS: 0.85 (0.56–1.31)	0.008; 0.46
		cetuximab		2.2 mos.	8 mos.
	WT	BSC versus	2+	1.9 mos.	5 mos.	PFS: 0.32 (0.21–0.49); OS: 0.52 (0.34–0.8)	<0.001; 0.003
		cetuximab		5.1 mos.	9.8 mos.
	MUT	BSC versus	0/1	1.9 mos.	5 mos.	PFS: 0.97 (0.65–1.46); OS: 1.47 (0.95–2.27)	0.89; 0.08
		cetuximab		1.8 mos.	4.0 mos.
	MUT	BSC versus	2+	1.9 mos.	5 mos.	PFS: 0.82 (0.52–1.3); OS: 0.82 (0.47–1.41)	0.89; 0.46
		cetuximab		1.8 mos.	6.6 mos.

WT: wild type, MUT: mutated, PFS: progression-free survival, and OS: overall survival.